CRHvsNiagen Bioscience

CRH and NAGE stock compared: price, dividend, valuation and results, from SEC filings.

CRH (CRH) has a market value of $60.5B and Niagen Bioscience (NAGE) $150M. Over the last year, with dividends, CRH moved -13.9% and NAGE -72.0%. The P/E is 17.0 for CRH and 14.6 for NAGE. Dividend yield: CRH 1.72%, NAGE none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CRH$60.5B

    NAGE$150M

    CRH is 404 times NAGE

  • Revenue, 12 months

    CRH$39.0B

    NAGE$122M

    CRH is 319 times NAGE

  • Net income, 12 months

    CRH$3.6B

    NAGE$10M

    CRH is 350 times NAGE

  • Operating margin

    CRH13.7%

    NAGE3.9%

    9.8 points apart

  • ROIC

    CRH9.2%

    NAGE5.6%

    3.6 points apart

  • P/E

    CRH17.0

    NAGE14.6

    CRH is 1.2 times NAGE

  • Dividend yield

    CRH1.7%

    NAGE0.0%

    1.7 points apart

  • 5-year return

    CRH+109.9%

    NAGE-66.4%

    176.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CRH+109.9%

NAGE-66.4%

10020030020222023202420252026
Returns by period
PeriodCRHWith dividendsNAGEWith dividends
1 year since November 17, 2025-13.9%Price -15.3%-72.0%Price -72.0%
3 years since November 17, 2023+62.5%+17.6% a yearPrice +53.8%+35.7%+10.7% a yearPrice +35.7%
5 years since November 17, 2021+109.9%+16.0% a yearPrice +83.7%-66.4%-19.6% a yearPrice -66.4%
10 years since November 21, 2016+256.7%+13.6% a yearPrice +174.6%-22.1%-2.5% a yearPrice -22.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CRHCRHNAGENiagen Bioscience

Valuation

CRHNAGE
Valuation
Price$90.54$1.87
Market value$60.5B$150M
Enterprise value (EV)$75.7B$80M
P/E17.014.6
P/E, 5-year median16.0–
P/B2.41.8
EV/EBIT14.216.8
Free cash flow yield4.2%–

Results and growth

CRHNAGE
Results and growth
Revenue, 12 months$39.0B$122M
Net income, 12 months$3.6B$10M
Free cash flow, 12 months$2.5B–
Earnings per share, 12 months$5.32$0.12
Revenue growth, year on year5.3%30.0%
Revenue growth a year, past+7.7%over 5 years+16.9%over 5 years
EPS growth a year, past-47.8%over 5 years–

Margins and returns on capital

CRHNAGE
Margins and returns on capital
Gross margin36.2%63.9%
Operating margin13.7%3.9%
Net margin9.2%8.4%
ROIC9.2%5.6%
ROE15.0%13.0%

Balance sheet

CRHNAGE
Balance sheet
Cash$5.1B$70M
Total debt$21.6B$2.1M
Net debt / EBITDA2.0-12.9
Interest cover6.3×–

Dividends and buybacks

CRHNAGE
Dividends and buybacks
Dividend yield1.7%–
Dividend per share, 12 months$1.56–
Dividend growth a year, past––
Buyback yield2.0%0.2%
Shareholder yield3.7%0.2%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CRH or NAGE

Didn't find what you were looking for?

Ask us
Which is bigger, CRH or Niagen Bioscience?

By market value, CRH ($60.5B) is about 404.0 times Niagen Bioscience ($150M), at today's prices.

How did CRH and NAGE stock do over the last 10 years?

Since November 21, 2016, CRH's price moved +174.6% and NAGE's -22.1%. With dividends: CRH +256.7% (+13.6% a year), NAGE -22.1% (-2.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, CRH or NAGE?

The dividend yield at today's price is 1.72% for CRH and none for Niagen Bioscience. Over the last twelve months they paid $1.56 and – per share.

What is the P/E of CRH and NAGE?

At today's price, the P/E is 17.0 for CRH and 14.6 for NAGE. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, CRH or Niagen Bioscience?

Over the last twelve months, the net margin was 9.2% for CRH and 8.4% for Niagen Bioscience, and the operating margin 13.7% and 3.9%. Revenue was $39.0B and $122M.

Which is the better investment, CRH or Niagen Bioscience?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.